Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

New incentives and tax benefits can boost R&D ecosystem for new drug development in India, says GlobalData

India has recently sought feedback from the top pharmaceutical companies to make regulatory changes that offer specific tax benefits for specialized research. With the government’s inclination towards promoting domestic R&D, new incentives and revising the current weighted tax deductions can boost the R&D ecosystem for new drug development in India, says GlobalData, a leading data […]
Read more

High incident cases of invasive pneumococcal disease in India is result of lack of country-wide vaccination, says GlobalData

Invasive pneumococcal disease (IPD) presents a significant public health concern globally. India leads the way with the highest number of diagnosed incident cases of IPD, says GlobalData, a leading data and analytics company. The company’s latest report ‘Pneumococcal Vaccines: Epidemiology Forecast in Asia-Pacific Markets to 2028’, reveals that there were more than two million diagnosed […]
Read more

An estimated 330m people, 15% of the 9MM population, face risk of severe COVID-19, says GlobalData

Following the recent news that the coronavirus (COVID-19) has now spread across 176 countries with approximately 530,000 total confirmed cases worldwide as of 27.03.20; Katie Wrenn, Associate Epidemiologists at GlobalData, a leading data and analytics company, offers her view on the current challenges facing the 9MM: “We now know that severe and critical forms of COVID-19 […]
Read more

Novartis’ Zolgensma expected to generate global sales of $2.5bn by 2025 with new data set to bolster the drug’s uptake, says GlobalData

Novartis recently announced new anticipated long-term positive data for its one-time infusion gene therapy, Zolgensma (onasemnogene abeparvovec-xioi), which is set to help the drug generate global sales of $2.5bn by 2025 and lead the spinal muscular atrophy (SMA) market, says GlobalData, a leading data and analytics company. The data showed significant therapeutic benefit in patients with […]
Read more

Government investment will turnaround active pharmaceutical ingredients industry in India, says GlobalData

Following the news that India has approved US$1.3bn* (INR10Kbn) healthcare package to boost the domestic manufacturing of active pharmaceutical ingredients (API); Prashant Khadayate, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “The package, which is part of a turnaround strategy to reduce India’s dependence on China, will help boost the […]
Read more

Covid-19 outbreak in China threatens biopharma in-house manufacturing, says GlobalData

With several mega cap biopharma companies having their vital manufacturing steps in Chinese facilities, the novel coronavirus (Covid-19) outbreak is putting the complicated global biopharma industry’s supply chain under strain, says GlobalData, a leading data and analytics company. Supply chain problems in China include a largely quarantined workforce, delays in transporting materials and several other […]
Read more

95% of healthcare professionals concerned about coronavirus impact on their companies, says GlobalData

As the number of global coronavirus (COVID-19) cases continues to rise, governments around the world are taking unprecedented measures, to contain the spread and support their economies throughout the outbreak. These measures include billions worth of rescue packages, tax postponements, liquidity injections and interest rate cuts to new lows, says GlobalData, a leading data and analytics company. GlobalData’s […]
Read more

Coronavirus cases in US projected to reach 8.1 million in two weeks, with high-risk scenario totaling more than 21.8 million

Last week, the GlobalData epidemiology team conducted a three-scenario forecast model of the coronavirus (COVID-19) transmission in the US, with the moderate estimate projecting more than 228,500 cases by March 31 and two million in a high-risk scenario. However, developments in the last week have shown the actual increase in confirmed cases was significantly higher […]
Read more

Synairgen’s SNG001 will prevent cell damage in fight against coronavirus pandemic

Synairgen has received approvals from the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA) to conduct a trial of SNG001 (inhaled interferon-beta-1a) in coronavirus (COVID-19) patients. SNG001 will prevent cell damage in a similar fashion to that of multiple sclerosis (MS) patients, says GlobalData, a leading data and analytics company. Synairgen […]
Read more

APAC axial spondyloarthritis market to grow moderately over next decade due to uptake of expensive biologic therapies, says GlobalData

The axial spondyloarthritis (axSpA) market across the five growth markets (5GM*) in the Asia-Pacific (APAC) region will experience moderate growth over the next 10 years, which can be attributed to the increased uptake of expensive biologic therapies in India and China along with the imminent arrival of new interleukin-17 (IL-17) inhibitors and Janus kinase (JAK) […]
Read more

COVID-19 cases in US could total more than 228,000 by end of March

There has been an exponential increase of coronavirus (COVID-19) cases in the US since the beginning of March, from less than 70 to more than 4,000. In just two more weeks, there could be over 228,000 confirmed cases, says GlobalData, a leading data and analytics company. Kasey Fu, Director of Epidemiology at GlobalData, comments: “Depending […]
Read more

Tessa Therapeutics TT11 will replace stem cell transplants as standard of care in Hodgkin’s lymphoma

Tessa Therapeutics’ TT11 has become the first CAR-T therapy to receive the Food and Drug Administration (FDA) regenerative medicine advanced therapy (RMAT) designation and is set to become the leading cell-based therapy in Hodgkin’s lymphoma (HL), displacing the outdated stem cell transplants as the standard of care by 2024, says GlobalData, a leading data and analytics company. Miguel Ferreira, MSc, Oncology and Hematology Analyst at GlobalData, comments: “TT11, being the first CAR-T therapy to emerge from […]
Read more

Angina landscape shifting towards increased recognition of microvascular angina in clinical practice

Microvascular angina (MVA) is being increasingly recognized in clinical practice, says GlobalData, a leading data and analytics company. According to key opinion leaders (KOLs) interviewed by GlobalData, patients with exertional angina and symptoms strongly suggestive of coronary artery disease (CAD) were previously often disregarded since the diagnosis of chronic stable angina was highly related to […]
Read more

Supply disruption scares and price hikes wakeup call for India to reduce dependence on China for APIs, says GlobalData

The impact of the coronavirus (Covid-19) outbreak on industries ranging from technology to automotive has been the subject of intense analysis in the recent months. This has exposed dependence of India on China for its active pharmaceutical ingredient (API) requirements. For India’s pharma industry, which is staring at a probable supply chain disruption of APIs, […]
Read more
1 … 100 101 102 103 104 … 110